<div><div><div><br /></div><div>A Phase III, Randomized, Double-blind, Multicenter, Global</div><div>Study of Rilvegostomig or Pembrolizumab in Combination with</div><div>Platinum-based Chemotherapy for the First-line Treatment of</div><div>Patients with Metastatic Squamous Non-small Cell Lung Cancer</div><div>Whose Tumors Express PD-L1 (ARTEMIDE-Lung02; D702BC00001)</div></div><div><br /></div></div>

ARTEMIDE-Lung02

Comprehensive Cancer Center Mainfranken

Lungentumoren

Nicht-kleinzelliges Bronchialkarzinom (NSCLC)

Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)

Weitere

PD-1 (Programmed cell death protein 1)

PD-L1

Phase III

Herr Dr. Jens Kern

Frau Christiane Köhler

Frau Dr. med Barbara Schröder

Innere Medizin

Klinikum Würzburg Mitte gGmbH (Standort Missioklinik)

Erstlinie

Therapeutisch